FindTrial
Sign In

Influences of Somatostatin Analogues on the Morbidity of Pancreatic Fistula After Pancreaticojejunostomy: A Randomized, Double-blind, Placebo-controlled Trial

Influences of Somatostatin Analogues on the Morbidity of Pancreatic Fistula After Pancreaticojejunostomy: A Randomized, Double-blind, Placebo-controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12003047
Enrollment
Unknown
Registered
2012-11-15
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic carcinoma

Interventions

1:24 hours continuously intravenous octreotide injection 12ml+saline injection 50ml from postoperative day 1 to 7
2:24 hours continuously intravenous octreotide injection 12ml+saline injection 50ml from postoperative day 1 to 3, 24 hours continuously intravenous saline placebo 62ml from postoperative day 4 to 7
3:24 hours continuously intravenous saline placebo 62ml from postoperative day 1 to 7

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients who are in anticipation of pancreaticoenterostomy in Hepatobiliary and Pancreatic Surgery of West China Hospital, Sichuan University between January 2013 and December 2015.

Exclusion criteria

Exclusion criteria: 1. Patient did not undergo pancreaticoenterostomy; 2. Patient underwent total pancreatectomy; 3. Patient did not receive enough course of study drug.

Design outcomes

Primary

MeasureTime frame
Pancreatic fistul;—

Secondary

MeasureTime frame
Morbidity of totle complication;—

Countries

China

Contacts

Public ContactZeng Yong
zengyonghxyy@163.com+86 13881969933

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026